Handbook of Statistics in Clinical Oncology (eBook, ePUB)

Redaktion: Crowley, John

• Format: ePub

Produktbeschreibung

The third edition presents up-to-date statistical approaches to the design and analysis of oncology clinical trials. New topics include trial designs for targeted agents, Bayesian trial design, and the inclusion of high-dimensional data and imaging techniques. It also contains numerous figures and examples to better explain concepts.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Taylor & Francis eBooks
• Erscheinungstermin: 26. März 2012
• Englisch
• ISBN-13: 9781040058015
• Artikelnr.: 69996313

Autorenporträt

John J. Crowley is president and CEO of Cancer Research and Biostatistics (CRAB), Seattle, Washington, director of the SWOG Statistical Center, and a faculty member at the Fred Hutchinson Cancer Research Center. The author or coauthor of more than 350 refereed articles, book chapters, and other publications, Dr. Crowley is a fellow of the American Statistical Association and the American Association for the Advancement of Science and a member of the International Biometrics Society, the American Society for Clinical Oncology, and the International Association for the Study of Lung Cancer. He received his BA (1968) from Pomona College, Claremont, California, and his MS (1970) and PhD (1973) in biomathematics from the University of Washington, Seattle. Antje Hoering, PhD, is a senior biostatistician at Cancer Research and Biostatistics (CRAB), Seattle, Washington. She is also an affiliate faculty member in the Department of Biostatistics at the University of Washington and an affiliate investigator at the Fred Hutchinson Cancer Research Center. Dr. Hoering is the lead statistician of the SWOG Myeloma Committee, the SWOG Early Therapeutics Subcommittee, and the Stand Up To Cancer, Pancreatic Dream Team. She is the coordinating statistician for the Myeloma Institute for Research and Therapy, the International Myeloma Committee, and the Pancreatic Cancer Research Team. She serves as a consultant on a variety of industry-sponsored studies and has been the biostatistics representative on two Type B meetings with the FDA. She is member of the American Statistical Association, the International Biometrics Society, and the International Myeloma Society. She received her BS (1985) from the University of Tubingen, Germany, her MS (1988) in physics from Oregon State University, Corvallis, and her PhD (1991) in physics from the Max Planck Institute for Theoretical Nuclear Physics, Heidelberg, Germany. She transitioned into biostatistics with a three-year NRSA postdoctoral fellowship with the Department of Biostatistics at the University of Washington and the Fred Hutchinson Cancer Research Center.

Inhaltsangabe

Choosing a Phase I Design. Dose Finding Designs Based on the Continual
Reassessment Method. Pharmacokinetics in Clinical Oncology: Statistical
Issues. Statistics of Phase 0 Trials. CRM Trials for Assessing Toxicity and
Efficacy. Seamless Phase I/II Trial Design for Assessing Toxicity and
Efficacy for Targeted Agents. Overview of Phase II Clinical Trials. Designs
Based on Toxicity and Response. Designs Using Time to Event
Endpoints/Single Arm versus Randomized Phase II. Phase II Selection
Designs. Phase II with Multiple Subgroups: Designs Incorporating Disease
Subtype or Genetic Heterogeneity. Phase II/III Designs. On Use of
Covariates in Randomization and Analysis of Clinical Trials. Factorial
Designs with Time to Event Endpoints. Early Stopping of Clinical Trials.
Noninferiority Trials. Phase III Trials for Targeted Agents. Adaptive Trial
Designs. Design of a Clinical Trial for Testing the Ability of a Continuous
Marker to Predict Therapy Benefit. Software for Design and Analysis of
Clinical Trials. Cure-Rate Survival Models in Clinical Trials. Design and
Analysis of Quality of Life Data. Economic Analyses alongside Cancer
Clinical Trials. Structural and Molecular Imaging in Cancer Therapy
Clinical Trials. Prognostic Factor Studies. Predictive Modeling of Gene
Expression Data. Explained Variation and Explained Randomness for
Proportional Hazards Models. Prognostic Groups by Tree-Based Partitioning
and Data Refinement Methods. Risk Calculators. Developing a Score Based
upon Gene Expression Profiling and Validation. Analysis of DNA Microarrays.
Methods for SNP Regression Analysis in Clinical Studies: Selection,
Shrinkage, and Logic. Forensic Bioinformatics. Index.